Introduction
The prostate contains the highest concentration of zinc of any soft tissue and secretes high amounts of zinc in the prostatic fluid. Zinc concentrations in malignant prostate tissues are about 10-25% of that in healthy prostates [1] , suggesting that high zinc concentrations may be essential for the maintenance of prostate health. The use of prostatic or prostatic fluid zinc levels as a diagnostic tool for prostate cancer screening that may be more reliable than prostate-specific antigen (PSA) is currently being explored [2, 3, 4 ]. For example, zinc levels in normal patients, prostate and prostatic fluid are approximately 3 and 9 mmol/l, respectively. In cancer patients, zinc levels are more than 90% decreased. In contrast to PSA, zinc levels do not decrease with other prostatic diseases such as benign prostate hyperplasia. Thus, it has been postulated that the use of low prostatic fluid zinc (<1 mmol/l) in combination with other markers such as low citrate concentrations may have a greater specificity as a biomarker to prostate cancer [4 ] . Although the results from epidemiologic studies have been mixed regarding the association between zinc intake and the risk of prostate cancer, experimental evidence strongly suggests that zinc plays roles in prostate cell functions and survival. However, the specific functions of zinc in the prostate and the mechanisms by which zinc maintains prostate health are still unclear. Several mechanisms by which zinc may protect prostate cells from malignancies have been proposed, including zinc as an inhibitor to mitochondrial aconitase (m-aconitase) activity, apoptogenic effects and as a protector for DNA integrity.
The purpose of the current article is to review the primary mechanisms that have been proposed for the functions of zinc in the prostate and summarize the recent epidemiologic and experimental findings in the field of zinc and prostatic cancer.
Zinc suppresses overall energy production in prostate cells Costello et al. [5, 7, 8] have found that zinc in the prostate reduces the activity of m-aconitase and inhibits terminal oxidation in the electron transport chain. The inhibitory effect of zinc on m-aconitase may contribute to the properties of high citrate secretion and low respiration in the prostate [5, 7] . Zinc depletion in the prostate may remove the inhibitory effects on citrate oxidation and terminal oxidation, and increase cellular respiration. Thus, decreases in cellular zinc levels in the prostate epithelial cell and subsequent release of the inhibition of aconitase activity could result in an elevated cell respiration that favors cell growth and differentiation and enables these cells to manifest their malignant properties [8] .
Zinc increases apoptogenic effects and suppresses tumor progression
Zinc depletion induces apoptosis in some mammalian cells. The possible mechanisms include defects in growth factor signaling pathways, activation of caspases and induction of the intrinsic pathway of apoptosis [9] . However, zinc has an opposite effect on cell growth in the prostate; zinc in the prostate induces mitochondrial apoptogenesis and reduces cell growth. Costello et al. [5, 7, 8] evaluated the effects of exposure to physiological levels of zinc on mitochondrial apoptogenesis in three human prostate cell lines: PC3 (advanced metastatic tumor), benign prostate hyperplasia (BPH) and normal human prostate epithelial cells (HPR-1). They found that zinc only induced apoptosis in PC3 and BPH cells but not in HPR-1, and gene expression profiles in response to zinc were cell-type specific [10] . The effects of zinc on apoptosis in the prostate cancer cells may be exerted through the modulation of expression of Bax and its binding with the mitochondrial membrane [11 ] and the subsequent release of cytochrome c from mitochondria that initiates the caspase cascade leading to apoptosis [12] . These studies demonstrate that the accumulation of cellular zinc in the prostate has a direct effect on the mitochondria by facilitating a Bax-associated pore formation process that initiates mitochondrial apoptogenesis.
Other studies have suggested that zinc may suppress prostatic tumor progression by decreasing NF-kB activity and the subsequent expression of angiogenic and prometastatic cytokines such as vascular endothelial growth factor (VEGF), IL-6 and IL-8 [13 ] . NF-kB is a transcription factor that regulates numerous genes, including ones involved in cell proliferation/tumor growth, inflammatory response, metastasis and angiogenesis. Constitutive activation of NF-kB is common to many cancer malignancies. The addition of physiological levels of zinc effectively inhibited NF-kB activation and sensitized PC3 and DU145 cells to TNF-a and paxitaxel-induced cell death [14] . It has been proposed that zinc supplementation induces phosphorylation of the members of three major mitogen-activated protein kinase (MAPK) subfamilies [extracellular signal-regulated kinases 1 and 2 (ERK 1/2), c-Jun N-terminal kinase (JNK) and p38] while blocking the degradation of the inhibitory subunit of NF-kB. Downstream targets of NF-kB that are major proangiogenic and prometastatic molecules, including adhesion molecules, VEGF, IL-6, IL-8 and matrix metalloproteinases (MMP-9), were also decreased with zinc treatment [13 ,15] . Thus, increased intracellular zinc levels in the prostate may have important functions in inhibiting the angiogenic and metastatic potential of malignant cells. Accordingly, decreases in intracellular zinc levels could have serious implications on cancer progression. Indeed, studies have shown that zinc deficiency decreases the efficacy of chemotherapeutics such as paclitaxel in prostate cancer cells [16] .
Zinc protects DNA integrity in the prostate
The general functions of zinc in the maintenance of DNA integrity may be also very important for prostate health. Zinc depletion in cells including normal PrEC increased DNA strand breaks [17, 18, 19 ]. Our lab has recently shown that dietary zinc depletion (4 mg/day for 6 weeks) in healthy men significantly increased DNA damage in peripheral blood cells, and zinc repletion (11 mg/day for 4 weeks) reversed the DNA damage back to the baseline levels [20 ] . As zinc is an essential component in numerous transcription factors, antioxidant defense enzymes and DNA repair proteins, zinc may protect DNA integrity through two different mechanisms: zinc has antioxidant properties and suppresses the generation of oxidative damage, and zinc is essential for DNA damage responses and helps repair DNA damage or remove damaged cells.
It has been established that zinc has an antioxidant capacity, and that zinc depletion in rats generates carbon-centered free radicals in lung microsomes and oxidatively modified proteins and lipids in various tissues [21] [22] [23] . Studies in our lab have shown that both severe [24] and marginal zinc depletion increases F 2 -isoprostanes in rat plasma. The mechanisms for the antioxidant functions of zinc include: protection of sulfhydryl groups from oxidation, thereby maintaining normal functions of proteins; zinc maintains the reductive intracellular environment through the modulation of thiol status [22, 25] ; zinc antagonizes the activity of divalent transition metals including iron and copper, and prevents the deleterious free-radical reactions (e.g. Fenton reaction); and zinc regulates the expression of metallothionein [26, 27] and Cu-Zn superoxide dismutase (SOD) activity. Therefore, the high zinc levels may protect the prostate from oxidative stress by both suppressing the generation of free radicals and promoting the removal of free radicals. However, no in-vivo studies to date have been performed to evaluate the effects of zinc deficiency in the prostate on oxidative stress and DNA damage. Recent findings from our laboratory have shown that marginal dietary zinc depletion increases DNA damage in the prostate of chronic exercising rats (unpublished data).
Normally, the accumulation of DNA strand breaks and DNA adducts stimulate cellular responses to repair the DNA damage or to remove the damaged cells. These cellular responses to DNA damage are triggered by multiple pathways, including DNA repair pathways, initiation of cell cycle arrest and apoptosis and the induction of multiple genes. Zinc depletion may interfere with some of these cellular responses and potentiate the accumulation of DNA damage. First of all, zinc depletion may influence cell cycle arrest and apoptosis by regulating cell signaling pathways. For example, zinc deficiency decreases the circulating level of insulin-like growth factor-1 (IGF-1) [28] , disrupts intracellular receptor tyrosine kinases (RTKs) signaling transduction pathways [29] and thymidylate/thymidine kinase expression [30] , thereby affecting cell proliferation and survival.
Second, zinc deficiency may impair DNA repair functions. Many proteins involved in DNA repair pathways are zinc-containing metalloproteins, such as tumor suppressor gene p53, xeroderma pigmentosum A (XPA), replication protein A (RPA) and poly-ADP ribose polymerase (PARP). These proteins are involved in DNA repair pathways of damage recognition, nuclear excision repair (NER) or base excision repair (BER). As zinc is essential for the function of some DNA repair proteins, zinc depletion may impair the activity of these proteins and interfere with the DNA repair functions.
Zinc depletion in normal PrEC cells altered the expression of genes involved in DNA damage repair and responses, such as tumor protein p73 (TP73), metal response element 11a (MRE11A), X-ray repair complementing defective repair in Chinese hamster cells 4 (XRCC4), breast cancer 2, early onset (BRCA2) and TP53 [19 ] . Among them, p53 is one of the zinc-containing tumor suppressors and plays an essential role in regulating DNA repair, cell proliferation and cell death [31] . Mutations in the DNA-binding domain of p53 protein are found in many tumor cells [31] , and zinc is located in the DNA-binding domain and is essential for the DNA-binding activity of p53. Although p53 is consistently induced in zinc-depleted cells, including normal PrEC, the DNA-binding activity of nuclear p53 is impaired with zinc deficiency [17, 18, 19 ]. One possible mechanism may be that decreased intracellular zinc interferes with the incorporation of zinc ion to the DNA-binding domain of p53, so that p53 is deprived of DNA-binding capacity and is unable to function normally in cellular activities such as DNA repair and cell apoptosis.
Thus, zinc may directly suppress the generation of oxidative DNA damage through its antioxidant properties and, at the same time, affect the activities of both zincdependent and zinc-independent proteins that are involved in DNA damage repair or cell apoptosis. Altogether, in the presence of low intracellular zinc, the accumulation of DNA damage may be substantially increased and thereby may predispose the prostate cells to the development of cancer.
Zinc transporters and prostate cancer
Zinc homeostasis is maintained by the activities of a family of zinc transporters (ZnTs) in the cell plasma membrane and intracellular organelles. At least 10 ZnTs and 14 Zip family members have been identified in mammals, and their tissue expression, cellular localization and regulation are very different [32 ] .
As it has been recognized that high zinc levels are essential for prostate health, a loss of function or dysregulation of certain ZnTs would result in the impairment of zinc homeostasis and possibly predispose prostate cells to the development of cancer. Recent studies have identified an association between ZnT expression and prostate cancer. Dysregulation of ZnTs, including ZnT1, ZnT3, Zip1, Zip2 and Zip3, has been found to be associated with the low intracellular zinc content in human prostate cancer tissues or cell lines. Human ZIP1 (hZIP1), hZIP2 and hZIP3 gene and/or protein expressions are downregulated in human prostate adenocarcinomatous glands and malignant cell lines compared with normal [33, 34 ] . In addition, tumorigenic human prostate epithelial cell lines (RWPE2) had decreased ZIP1 protein expression and redistributed intracellular ZIP3 in comparison with the nontumorigenic human prostate epithelial cell line RWPE1 [35] . Moreover, overexpression of hZIP1 in the tumorigenic RWPE2 prostate cells increased the intracellular zinc concentrations, induced cell apoptosis and suppressed cell growth [35] . A recent study done by Golovine et al. [36 ] also found that overexpression of hZip1 in PC3 cells inhibits tumor growth in vivo in C.B17/ lcr-scid mice inoculated subcutaneously with PC3 xenografts. NF-kB activity and NF-kB pathway-dependent angiogenesis and prometastatic cytokines expression were also suppressed in these transfected PC3 cells. In terms of the ZnT family members, lower levels of ZnT1 gene are also found in human prostate cancer tissues [37] and in the androgen-independent subline of LNCaP cells [38] . ZnT4 gene expression is also decreased in human prostate BPH and carcinoma tissues [39] . These studies provide important preliminary evidence for the potential role of specific ZnTs in prostate cancer progression.
Zinc intake and the risk of prostate cancer
Several large observational cohort studies [40] [41] [42] have found that plasma zinc concentrations or dietary zinc intakes are inversely associated with cancer or all-cause mortality risks. Specifically for prostate cancer, a casecontrol study done by Kristal et al. [43, 44] observed that the usage of individual zinc supplements was associated with reduced prostate cancer risk and BPH. Recently, the Vitamins And Lifestyle (VITAL) cohort study found that long-term usage of zinc supplements was not associated with reduced prostate cancer risk, but supplemental zinc was associated with reduced risk of advanced prostate cancer [45 ] . Dietary zinc was associated with prostate cancer in this study. In addition, a study [46] done in South Carolina found that an area with lower soil zinc content had higher prostate cancer rate. However, several cohort and case-control studies have also observed that long-term and/or high-dose zinc supplements increase the risk of prostate cancer [47 ] . Reasons for these mixed results could be due to several factors. First, the current upper limit for zinc is 40 mg/day of zinc. At these levels of zinc or higher, it is possible that zinc may interfere with copper absorption and predispose individuals to copper deficiency [48] . It is possible that maintaining 'adequate' zinc status is critical for prostate function, but high supplementation levels may be more detrimental. Second, an accurate and sensitive biomarker for zinc status does not exist in humans, making the assessment of baseline zinc status in the observed populations very difficult. Commonly used biomarkers such as plasma/ serum zinc levels are problematic in that due to tight homeostatic control, circulating levels of zinc do not respond consistently to changes in dietary zinc and may not be reliable indicators of individual zinc status [49, 50 ] . Thus, the establishment of baseline zinc status in intervention studies is difficult. Other studies examining other antioxidant nutrients, such as vitamins E and C, have found that baseline status has a significant impact in response to supplementation [51] . Thus, in zinc supplementation trials, it becomes extremely difficult to interpret whether you are observing a repletion effect (i.e. reversal of a low zinc status to adequate) or a true zinc supplement effect. On the basis of the National Health and Nutrition Examination Survey (NHANES) data, it is estimated that 12% of the population are not consuming the estimated average requirement (EAR) for zinc. In the populations over the age of 55 years, this number rises to over 40% [52] . Although the commonly used zinc biomarkers such as plasma zinc have been criticized for lack of sensitivity and specificity, functional biomarkers such as IL-2 gene expression in mononuclear cells [53] have been proposed to be good indicators for zinc status. Therefore, future studies using accurate biomarker to reflect zinc status would help clarify the association between zinc status and risk of prostate cancer.
Conclusion
On the basis of numerous studies, it appears clearly that zinc has an important function in the prostate. A loss of intracellular zinc levels in the prostate, either through low dietary intake, abnormalities in ZnT expression or other conditions that impair zinc metabolism, could have serious deleterious effects with respect to prostate cancer development. Although the connection between dietary zinc or zinc supplements intake and risk of prostate cancer is still unclear and inconclusive, a growing body of evidence supports that high zinc levels in the prostate are essential for prostate health and protect prostate cells from malignancies. The possible mechanisms include the effects of zinc on the inhibition of terminal oxidation, induction of mitochondrial apoptogenesis, suppression of NF-kB activity and maintenance of DNA integrity. Moreover, because of the importance of zinc homeostasis to prostate health, a number of ZnTs have been identified as tumor suppressors in the prostate. A 'U-shaped' curve with respect to zinc status and prostate cancer risk may exist, in which both low zinc and 'super'-supplemented levels above the upper limit of zinc may be associated with increased prostate cancer risk. We hypothesize that maintaining adequate zinc status is critical for prostate health. As many of the studies have been performed in vitro, future studies on the effects of zinc status on prostate function in normal animals or prostate cancer models are needed. Moreover, the identification of sensitive and specific zinc biomarkers would significantly aid in the design and interpretation of human clinical studies.
